Pharma Tech Outlook: Pharma Tech Magazine

Bioelectronica: Lab-on-a- Chip for Drug Discovery and Diagnostics

Top 10 Drug Discovery and Development Solution Companies - 2019


The inception of robust and innovative techniques in drug discovery and development is revolutionizing the pharmaceutical sector. The speed and accuracy facilitated by groundbreaking technologies such as data science and blockchain are enabling organizations to break free from outdated legacy systems and embrace advanced operational capabilities. With the proliferation of digitalization, it is imperative to gain an in-depth understanding of the increasingly competitive commercial drug development environment.

To inform pharmaceutical organizations regarding the best practices in drug discovery and development, Pharma Tech Outlook has compiled a list of top 10 drug discovery and development solution providers and services companies that are identifying missed revenue opportunities and helping their clients improve growth prospects. Equipped with innovative technological capabilities and robust offerings, these companies are constantly proving their mettle in the pharmaceutical sector. We hope this edition of Pharma Tech Outlook helps you build partnerships that you and your firm need to foster a new and advanced approach that motivates pharma professionals to better drive productivity and efficiency throughout the sector.

We present to you Pharma Tech Outlook, “Top 10 Drug Discovery and Development Solution Providers – 2019,”

    Top drug Discovery and Development solution Companies

  • A research-stage biotechnology company building next-generation digital tools for drug discovery, diagnostics, and cell sorting. The company is one of the leading entities using the advances behind Moore’s law and passing those benefits on to biochemists. Bioelectronica invented “electrofluidic chips,” which are built through planar processes to solve a core problem in biochemistry and cell biology: manipulating small (nanoliter) volume of liquids and detecting chemical or biochemical reactions inside them. This is an inexorable advancement for drug developers and other cell biologists as electrofluidic chips are scalable to billions of nanopore channels, which can be used to transport and sort single cells based on their secretion rate and other properties

  • With a focus on accelerating clinical trials and cost benefits to trial owners, BloqCube, a pharma technology provider, is changing the current state of digital implementations by taking the tests to the patient rather than them being treated at trial sites. As strict regulations come into play in terms of data management, BloqCube uses blockchain to safeguard all information in a secure and decentralized manner, reassuring stakeholders that their information is always safe and well protected. For pharma institutions and drug development centers working on areas that need the most medical attention, BloqCube addresses critical pain points that are plaguing their operational workflows

  • Provides a full suite of technical capabilities and domain expertise in all phases of anti-infective drug development

  • Backed by a robust interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers, Intelligencia leverages a proprietary methodology to deliver its solution to the researchers. This platform pulls information from hundreds of characteristics that are fed into various algorithms to pick up trends in order to answer the questions of drug developers. Whether it be to assist in prioritization of pre-clinical assets to take forward to the clinic, help to make critical go/no-go decisions on development or to evaluate potential compounds to in-license, Intelligencia provides an objective outside view deemed valuable by pharma and biotech today

  • NTxBio’s science is redefining the discovery and production of biologic materials to be infinitely faster, purer, and more affordable for everyone. They are moving beyond empowering biopharma to impact global health and humanity. Large scale production of pharmaceuticals follows the convention of growing material in an environment typically hosted by E. coli bacteria. From insulin to vaccines to modern drugs, this complicated, time-consuming, and inefficient process is the reason behind the extreme costs and long delays. Not to mention the vast and sometimes toxic waste stream produced with each batch, NTx’s science is changing it all

  • Rosa was first found in 2002 and remained an employee-owned, science-focused, and client-friendly firm. In present times, Rosa is the worldwide commercial leader in PhysioPD-style Research, with comprehensive basic biology and therapeutic experience, industry-leading modeling expertise, and repeat research engagements with a majority of the Top 20 pharmaceutical companies. Rosa’s staff brings more than a century of aggregate experience in applying PhysioPD Research to the inherent challenges faced by drug developers and has authored hundreds of scientific posters, conference presentations, relevant patents, and peer-reviewed publications

  • BioXcel Therapeutics

    BioXcel Therapeutics

    BioXcel Therapeutics is a clinical-stage biopharmaceutical company that uses novel AI, to identify the next wave of medicines across neuroscience and immuno-oncology. They are focused on leveraging cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BioXcel Therapeutics employs a unique AI platform to minimize therapeutic development costs and potentially accelerate timelines while aiming to increase the possibility of success. Their approach leverages existing approved drugs and clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices

  • BlueCatBio


    The award-winning BlueWasher of BlueCatBio uses centrifugation instead of aspiration to remove liquids from all plate formats, including 1536w, eliminating background and variability at their (assay) sources. Engineered and built in Germany to the highest quality standards, BlueWasher offers unprecedented control and reproducibility of non-contact plate drying, media changes, and bead washes through an intuitive and user-friendly graphical user interface and is built to be easily automated. BlueWasher instantly improves screening economics without complex assay or automation changes, delivering unparalleled ROI and a direct boost to overall drug discovery productivity

  • Tempo Bioscience

    Tempo Bioscience

    Established in 2013, Tempo Bioscience, Inc (Tempo) develops human adult stem cell-based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in-vitro diagnostics, and biomarker development. Their in-house developed proprietary technologies and cell-based products serve as valuable tools for the Biotechnology and Pharmaceutical industry. Tempo Bioscience (Tempo) develops cutting-edge 2D&3D human cellular technologies to serve the needs of a variety of preclinical research and drug development pipelines across unique and diverse therapeutic and diagnostic areas. Tempo offers services and alliances based on advanced technological platforms and a range of capabilities

  • XtalPi


    XtalPi is a pharmaceutical technology organization that is recreating the industry’s approach to drug research and development with the help of its Intelligent Digital Drug Discovery and Development (ID4) platform. With interwoven quantum physics, AI, and high-performance cloud computing algorithms, XtalPi’s ID4 platform offers accurate predictions on the physicochemical and pharmaceutical properties of small-molecule candidates for solid-form selection, drug design, and other critical aspects of drug development. XtalPi is committed to improving the efficiency, precision, and success rate of drug research and development, and contributing to a healthier society worldwide